October 3, 2019
TGen-HonorHealth Clinical Trial Shows Tumor Shrinkage in 71 percent of Patients with Late-Stage Pancreatic Cancer
Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.
Read MoreSeptember 20, 2019
American Airlines and Stand Up To Cancer Team Up With Hyatt, Universal Orlando Resort to Give Families Affected by Cancer with Weekend to Remember
Today marks the inaugural flight of the American Airlines official Stand Up To Cancer Airbus 321 that features 22,627 names of cancer survivors, patients and those we have lost to cancer. Names were submitted by the public throughout the month of July, all of whom donated $25 or more to have their loved one’s name added to the plane, resulting in more than $825,000 for cancer research.
Read MoreSeptember 16, 2019
Stand Up To Cancer Launches Two Research Teams To Accelerate Clinical Trials for Triple-negative Breast Cancer and Metastatic Prostate Cancer
Stand Up To Cancer (SU2C) is launching teams of experts to lead innovative attacks on two types of cancer that have defied conventional treatment: triple-negative breast cancer (TNBC) in women and metastatic prostate cancer in men.
Read MoreSeptember 11, 2019
Stand Up To Cancer Hails Dr. Dennis J. Slamon, Pioneer In Modern Treatment of Breast Cancer and Leader SU2C Breast Cancer Dream Team
Stand Up To Cancer (SU2C) congratulates Dennis J. Slamon, MD, PhD, leader of the SU2C Breast Cancer Dream Team, on receiving the 2019 Lasker-DeBakey Clinical Medical Research Award for his development of Herceptin, a targeted treatment for HER2-positive breast cancer.
Read MoreAugust 7, 2019
Stand Up To Cancer And Society For Immunotherapy Of Cancer Announce Postdoctroal Convergence Scholar Fellowship Award Recipients
Stand Up To Cancer (SU2C) and the Society for Immunotherapy of Cancer (SITC) today announced five Convergence Scholar Fellowship Award recipients. These early career investigators will work with leading experts in physical and biomedical science to better understand the interplay between the immune system and cancers as they develop.
Read MoreJuly 9, 2019
Make Some Time and Start Something Priceless with Mastercard and Stand Up To Cancer
The opposing All-Star managers are coming together to encourage people to dine out with long lost friends, family, teammates - or really anyone - and remind them to make sure they bring a Mastercard so together we can support cancer research. For the 10th consecutive year, Mastercard is collaborating with SU2C and inviting cardholders to give back through the simple act of dining out.
Read MoreJuly 9, 2019
Stand Up To Cancer & Major League Baseball Launch New PSA For Celebration Of 11 Years Of Collaboration – And “For All The Moments We Stand Up”
Stand Up To Cancer (SU2C) is set to launch a brand new public service announcement (PSA) campaign in collaboration with founding donor, Major League Baseball (MLB).
Read MoreJuly 1, 2019
Add A Name To A Plane: American Airlines Aims To Raise Valuable Funding For Stand Up To Cancer With Plane Naming Campaign
American Airlines will provide a once-in-a-lifetime opportunity to add a loved one’s name to one of its planes in honor of those who are cancer survivors, current cancer fighters and those who lost their battle with cancer.
Read MoreJune 12, 2019
Drs. Carpten and Pettigrew Are Named to Stand Up To Cancer Scientific Advisory Committee
Stand Up To Cancer (SU2C) with its Scientific Partner, the American Association for Cancer Research (AACR), announced two new members of the SU2C Scientific Advisory Committee (SAC): John D. Carpten, PhD, director of the Institute of Translational Genomics at the Keck School of Medicine of the University of Southern California (USC), and Roderic I. Pettigrew, PhD, MD, chief executive officer of Engineering Health (EnHealth) and executive dean for Engineering Medicine (EnMed), at Texas A&M University.
Read MoreJune 11, 2019
Stand Up To Cancer Hails FDA Approval of ALPELISIB + FULVESTRANT Combination For Patients With A PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer
Stand Up To Cancer (SU2C) welcomed the recent Food and Drug Administration (FDA) approval of alpelisib in combination with fulvestrant, the first and only new therapy for a difficult to treat form of advanced or metastatic breast cancer in both post-menopausal women and in men.
Read More